The Role of Genotoxicity in Infertility and Cancer Development

Message from the Guest Editors

Dear Colleagues,

Day after day, every individual is exposed to different chemicals and particles that react with our genetic material, causing myriad consequences for our health. Global industrialization together with the development of our health system has led to an exponential growth in the number of toxics we use for different matters. Innovative/systemic therapies widely used for different treatments are based on the use of genotoxics that directly influence the growth of our cells. Not only that, but genotoxicity is one of the principal factors to induce cancer and infertility in humans, mainly caused by radiation and chemicals, which can cause DNA damage and induce mutations and chromosomal rearrangements. Therefore, a better understanding of the molecular mechanisms related with genotoxicity and its regulation in cancer and infertility will help us understand how to develop potential therapeutic and preventive approaches.

In this Special Issue, our aim is to collect a series of research articles and reviews on the role of genotoxicity in cancer and infertility development.
Message from the Editor-in-Chief

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the Genes team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider Genes for your next genetics paper?

Author Benefits

Open Access: Free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: Covered by Science Citation Index Expanded (Web of Science) and Scopus. Citations are available in PubMed, full-text archived in PubMed Central.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 4.5 days (median values for papers published in this journal in the first half of 2019).

Contact Us

Genes
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland
Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/genes
genes@mdpi.com
@Genes_MDPI